During the COVID-19 pandemic, every mRNA vaccine used in Korea was imported from abroad.
That reliance raised real concerns about supply delays in an emergency.
In 2026, though, a domestically developed COVID mRNA vaccine is heading into phase 2 trials.
This article covers the latest progress on the Korea domestic COVID mRNA vaccine trial, why vaccine self-sufficiency matters, and how you can join a clinical trial yourself.

How far has the Korea domestic COVID mRNA vaccine trial come?
In July 2026, GC Biopharma (GC녹십자) submitted an application to Korea’s Ministry of Food and Drug Safety (MFDS, the country’s drug regulatory authority, similar to the US FDA) to start a phase 2 trial for its COVID-19 mRNA vaccine candidate, GC4006A.
This submission marks a major step forward for the Korea domestic COVID mRNA vaccine trial effort.
A clinical trial is a research process that tests a drug’s safety and effects in people. GC Biopharma was selected to run this phase 2 study under a government-backed program for pandemic mRNA vaccine development, jointly overseen by the Korea Disease Control and Prevention Agency (KDCA) and the Korea Health Industry Development Institute.
· GC Biopharma’s GC4006A: phase 2 starting in 2026, phase 3 application targeted for late 2027, final approval targeted by 2028
· Eyegene (아이진) consortium’s BMI2012: phase 1 running Dec 2025-Mar 2027, aiming for phase 2 approval
A consortium led by Eyegene is also developing BMI2012, a homegrown mRNA vaccine candidate targeting COVID-19 variants, under KDCA’s phase 1 support program.
Source: Hankyung, “GC Biopharma Submits Phase 2 IND for COVID-19 mRNA Vaccine,” 2026
Why does Korea need domestic vaccine self-sufficiency?
The Korea domestic COVID mRNA vaccine trial program exists partly because Korea has relied almost entirely on imported COVID mRNA vaccines, and a global shortage during a future pandemic could delay domestic supply.
Vaccine self-sufficiency means developing and producing vaccines with domestic technology to reduce dependence on outside supply chains. Through this support program, the government aims to build a local mRNA platform that can respond quickly to a future pandemic.
These domestic vaccines are still in clinical trials. Their safety and effectiveness haven’t been confirmed until final approval, so treat news coverage as reporting on a development, not a finished product.
CEPI, the international Coalition for Epidemic Preparedness Innovations, is also supporting Korea’s mRNA platform work as part of its “100 Days Mission” to compress future vaccine development timelines.
Source: CEPI, “CEPI supports novel mRNA vaccine development in Korea”
What phases does an mRNA vaccine clinical trial go through?
Drug trials in Korea generally move through phase 1, 2, and 3, and each phase checks something different.
The Korea domestic COVID mRNA vaccine trial follows this same three-phase structure.
Phase 1 is the stage that tests safety first, in a small group of healthy adults. GC4006A’s phase 2 trial will enroll healthy adults and older adults aged 19 to 85, comparing it directly against an already-approved vaccine to find the optimal dose and measure immune response.
✅ Phase 1: safety in a small group
✅ Phase 2: optimal dose and immune response
✅ Phase 3: effectiveness and safety in a large group
As a candidate moves through each phase, the participant pool grows and the data collected gets more detailed.
Source: Hankyung, 2026; Eyegene consortium press release, 2025
How can you participate in a clinical trial?
You can look up the Korea domestic COVID mRNA vaccine trial and other trials currently running in Korea through the Clinical Research Information Service (CRIS), operated by the KDCA.
CRIS is an online system that registers and publishes information on clinical trials and research conducted in Korea. It’s the World Health Organization’s 11th registered platform under the International Clinical Trials Registry Platform (ICTRP), and you can search it for trials currently recruiting participants.
✅ Confirm the trial has Institutional Review Board (IRB) approval
✅ Read the informed consent form carefully — it should explain the purpose, procedures, and possible side effects
✅ Check the eligibility criteria (age, health status, etc.)
✅ Know who to contact and what happens if you experience side effects
Joining a clinical trial, including the Korea domestic COVID mRNA vaccine trial, is a decision worth taking seriously — talk it through with the trial’s research team or your doctor before you sign up.
You can find related articles in the Medications & Supplements category.
Source: Korea National Institute of Health, “Clinical Research Information Service (CRIS) Introduction”
Frequently Asked Questions
1. When will the Korea domestic COVID mRNA vaccine trial lead to an approved vaccine?
GC Biopharma is targeting final approval by 2028, but the timeline could shift depending on trial results. There’s no confirmed launch date yet.
2. Do you get paid for joining a clinical trial?
Compensation, like participation fees or travel reimbursement, varies by trial. Contact the specific trial site directly for details.
3. Is it risky to join a clinical trial?
Every trial goes through IRB review and has a system for monitoring adverse events, but the possibility of side effects can’t be ruled out entirely. Get a full explanation before you decide.
4. How is the domestic mRNA vaccine different from imported ones?
The underlying mRNA platform works similarly, but developing and producing it domestically is what makes it a self-sufficiency milestone. Any difference in effectiveness can’t be confirmed until trial results are final.
5. Who’s eligible to join a clinical trial?
Eligibility criteria like age and health status vary by trial. Check CRIS or contact the trial site directly for accurate requirements.
References
(Hankyung), “GC Biopharma Submits Phase 2 IND for COVID-19 mRNA Vaccine” (GC녹십자, 코로나 mRNA 백신 임상 2상 IND 제출), 2026. Link
(Hankyung), “Eyegene Consortium Selected for KDCA’s Pandemic mRNA Vaccine Phase 1 Support Program” (아이진 컨소시엄, 질병청 ‘팬데믹 대비 mRNA 백신개발 임상 1상 지원사업’ 선정), 2025. Link
(Korea National Institute of Health), “Clinical Research Information Service (CRIS) Introduction”. Link
(CEPI), “CEPI supports novel mRNA vaccine development in Korea to protect against future Disease X”. Link
This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Please consult a qualified healthcare provider if you have health concerns.


















